Gabapentin for Alcohol Withdrawal Syndrome (NCT03012815) | Clinical Trial Compass
CompletedPhase 4
Gabapentin for Alcohol Withdrawal Syndrome
United States88 participantsStarted 2017-02-01
Plain-language summary
The current "gold-standard" for the management of alcohol withdrawal syndrome (AWS) is symptom-triggered administration of benzodiazepines. This method of treatment has several drawbacks that have been described in the literature. Thus benzodiazepine sparing agents have been evaluated for use in AWS. One of these agents that has not only shown benefit for AWS but also benefits on complete abstinence, reducing a return to heavy drinking, and cravings is gabapentin. In clinical practice at Mayo Clinic gabapentin is used for this purpose. Due to the limited reports of the safety and efficacy of a protocol involving gabapentin for AWS, a study to compare gabapentin to symptom-triggered lorazepam will be completed.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Prediction of Alcohol Withdrawal Severity Scale (PAWSS) score \>4.
✓. Adults age 18 or older.
✓. Sufficient understanding of English.
✓. Hospitalized on Hospital Internal Medicine or Generose.
Exclusion criteria
✕. Severe renal impairment (estimated CrCl \< 30).
✕. Intensive Care Unit (ICU) level of care.
✕. Not responsive due to alcohol intoxication or withdrawal.
✕. Already taking gabapentin more than 300 mg three times a day.
✕. Prescribed pregabalin.
✕. Primary seizure disorder.
✕. Acute benzodiazepine withdrawal.
✕
What they're measuring
1
Mean Length of Hospital Stay
Timeframe: Time to discharge or time to CIWA-Ar score < 10 for 36 hours (whichever came first) up to 240 hrs.
. Concurrent substance use disorders (such as opioid use disorder, stimulant use disorder) if the disorder is assessed to be clinically significant. Cannabis use disorder will be allowed.